Prescription drug · ANDA
Ceftazidime NDC 25021-127
Ceftazidime 1 g/1 · Injection, Powder, For solution · Intramuscular, Intravenous · Sagent Pharmaceuticals
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 25021-127-20 | 25021012720 | 25 VIAL in 1 CARTON (25021-127-20) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIALMarketed from May 15, 2008 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Ceftazidime
- Generic name (nonproprietary)
- ceftazidime
- Active ingredients
- Ceftazidime — 1 g/1
- Dosage form
- Injection, Powder, For solution
- Route
- Intramuscular, Intravenous
- Labeler
- Sagent Pharmaceuticals
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 062640
- Marketing start
- Listing expires
- Other FDA classes
- Cephalosporins (Chemical structure)
- Identifiers
- Product ID 25021-127_57ce314f-eda1-4438-8a50-2010d4d8aefdSPL ID 57ce314f-eda1-4438-8a50-2010d4d8aefdSPL set ID 112c5457-8d71-49f5-b531-9761d7d38c93RxCUI 1659283, 1659287UNII 9M416Z9QNR
- Pharmacologic class
- Cephalosporin Antibacterial
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N425021012720followed by a unit qualifier and the quantityPackage 25021-0127-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Ceftazidime for injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia coli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin-susceptible strains). Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including …
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 062640
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Ceftazidime | Ceftazidime 2 g/1 | Injection, Powder, For solutionIntravenous | WG Critical Care, LLC | 44567-236 |
| Ceftazidime | Ceftazidime 1 g/1 | Injection, Powder, For solutionIntramuscular, Intravenous | WG Critical Care, LLC | 44567-235 |
| Ceftazidime | Ceftazidime 6 g/1 | Injection, Powder, For solutionIntravenous | WG Critical Care, LLC | 44567-237 |
| Ceftazidime | Ceftazidime 2 g/1 | Injection, Powder, For solutionIntravenous | Sagent Pharmaceuticals | 25021-128 |
| Ceftazidime | Ceftazidime 6 g/30mL | Injection, Powder, For solutionIntravenous | Sagent Pharmaceuticals | 25021-129 |